AstraZeneca, Silence partner to bring siRNA therapies to extrahepatic tissues

AZ, Silence rekindle an old partnership with new deal for siRNA therapeutics

Thirteen years after they first teamed up, AstraZeneca and Silence are giving their partnership another shot with a new $80 million deal to develop siRNA therapeutics targeting the liver and extrahepatic tissues.

The deal is the second for AstraZeneca plc (LSE:AZN; NYSE:AZN) this year in RNA therapeutics as the company establishes its foothold in the modality through external innovation.

Silence Therapeutics Inc. (LSE:SLN) believes the deal could give it

Read the full 698 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers